A US government agency has hit back at a plan by Johnson & Johnson to change the way it pays discounts on drugs to hospitals participating in the 340B programme for healthcare systems s
Johnson & Johnson has three of its top-selling drugs in Medicare pricing negotiations – Stelara, Xarelto, and Imbruvica – but has said it does not expect a major hit to its finances nex
Bayer counted the cost of its expensive Roundup weedkiller settlement in the second quarter with a €9.5 billion net loss made worse by lower sales in its pharma and consumer he
